Article Sidebar

pdf
Date Published: 17/11/2025
Abstract Views: 83
Views pdf: 36
DOI: https://doi.org/10.51298/vmj.v555i3.16156
Issue
Vol. 555 No. 3 (2025)
Section
Các bài báo
How to Cite
Nguyễn, T. C., & Bạch, Q. K. (2025). OVERALL SURVIVAL AND FACTOR ASSOCIATED WITH TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION IN THE PERIOD 2019-2023. Vietnam Medical Journal, 555(3). https://doi.org/10.51298/vmj.v555i3.16156

OVERALL SURVIVAL AND FACTOR ASSOCIATED WITH TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION IN THE PERIOD 2019-2023

Thu Chang Nguyễn, Quốc Khánh Bạch

Main Article Content

Abstract

Purpose: To estimated the survival rate and indentify factors associated with treatment effectiveness in CML patients receving Imatinib over a 5 years period at the National Institue of Hemathology and Blood Transfusion. Patients and methods: this was a descriptive study of 798 CML patients with Ph (+) receving Imatinib in National Institute of Hematology and Blood Transfusion from January 1, 2019 to December 31, 2023. Results: At 5 years, the estimated rate of overall – survival was 89,5%, progress - free survival was 84,8%, event - free survival was 78,7%. Prognotic factor influencing treatment effectiveness and survival rate included risk grouping, Imatinib dose reduction and achieving early molecular response after 3 months. Conclusion: Treatment of chronic phase CML with Imatinib for patients not classified as high risk remains highly efective, helping to prolonged overall survival, progresstion free survival and event free survival.

Article Details

Keywords

Chronic Myeloid Leukemia, BCR-ABL, Imatinib, OS, PFS, EFS.

References

1. MW. Deininger (2008), “Chronic myeloid leukeumia: an historical perspective”, Hematology 2008 - American society of hematology education program book, 218.
2. M. Pfirrmann, M. Baccarani, S. Saussele và cộng sự (2016). Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia, 30 (1), 48 - 56.
3. Hướng dẫn chẩn đoán và điều trị bệnh lý huyết học (2022), Bộ y tế.
4. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34:966 - 84.
5. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to Imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65 [EuropePMCfree article] [Abstract] [Google Scholar]
6. Hughes de Lavanllade H, Apperley JF, Khorashad JS, et al (2008), “Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention - to - treat analysis”, J Clin Oncol, 26, 3358.
7. Nguyễn Thị Mỹ Hòa, Cồ Nguyễn Phương Dung, Nguyễn Quốc Thành (2014), Thời gian sống còn của bệnh nhân bạch cầu mạn dòng tủy điều trị với Imatinib Mesiglate trong thời gian 5 năm”, Y học Việt Nam số đặc biệt tháng 10, 267 - 275, 2014.
8. Long-term outcome following Imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study - PubMed (nih.gov).
9. G-CML-1211381. Evolving Treatment Paradigms in CML. An Overview of the 2nd - Generation TKI Pivotal Trials. Basel, Switzerland: Novartis Pharma AG; April 2019.
10. Eriko Sato, Noriyoshi Iriyama et al. The EUTOS long-term survival score predicts disease specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med 2020 Dec; 9(23): 8931 – 8939.